NightstaRx (Nightstar), a fresh spin-out from the University of Oxford, has launched with £12m ($20m) in backing from Syncona, a subsidiary of charity investor the Wellcome Trust. The company is focused on the development and commercialisation of therapies for degenerative conditions which affect vision. The first retinal dystrophy Nightstar will focus on is a gene…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
